Literature DB >> 24527810

Embryonic stem cell-derived haematopoietic progenitor cells down-regulate the CD3 ξ chain on T cells, abrogating alloreactive T cells.

Eun-Mi Kim1, Bob Miyake, Manish Aggarwal, Ruth Voetlause, Maia Griffith, Nicholas Zavazava.   

Abstract

Murine embryonic stem (ES) cell-derived haematopoietic progenitor cells (HPCs) engraft and populate lymphoid organs. In vivo, HPCs engraft across MHC barriers protecting donor-type allografts from rejection. However, the underlying phenomenon remains elusive. Here, we sought to determine the mechanism by which ES cell-derived HPCs regulate alloreactive T cells. We used the 2C mouse, which expresses a transgenic T-cell receptor against H2-L(d) to determine whether HPCs are deleted by cytotoxic T lymphocytes (CTLs). Previously, we reported that HPCs express MHC class I antigens poorly and do not express class II antigens. In vitro stimulated 2C CTLs failed to lyse H2-L(d) HPCs in a standard 4-hr (51) chromium release assay. Similarly, when the HPCs were tested in an ELISPOT assay measuring the release of interferon-γ by CTLs, HPCs failed to induce CTL degranulation. In addition, mice that were injected with HPCs showed a marked decrease in T-cell responses to alloantigen and CD3 stimulation, but showed a normal response to PMA/ionomycin, suggesting that HPCs impaired T-cell signalling through the T-cell receptor/CD3 complex. Here, we show that HPCs secrete arginase, an enzyme that scavenges l-arginine, leading to metabolites that down-regulate CD3 ζ chain. Indeed an arginase inhibitor partially restored expression of the CD3 ζ chain, implicating arginase 1 in the down-regulation of T cells. This previously unrecognized property of ES cell-derived HPCs could positively enhance the engraftment of ES cell-derived HPCs across MHC barriers by preventing rejection. Published 2014. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  T-cell down-regulation; arginase; embryonic stem cells

Mesh:

Substances:

Year:  2014        PMID: 24527810      PMCID: PMC4080958          DOI: 10.1111/imm.12268

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  22 in total

1.  HOXB4 enforces equivalent fates of ES-cell-derived and adult hematopoietic cells.

Authors:  Sandra Pilat; Sebastian Carotta; Bernhard Schiedlmeier; Kenji Kamino; Andreas Mairhofer; Elke Will; Ute Modlich; Peter Steinlein; Wolfram Ostertag; Christopher Baum; Hartmut Beug; Hannes Klump
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-10       Impact factor: 11.205

2.  Immunogenicity and engraftment of mouse embryonic stem cells in allogeneic recipients.

Authors:  Sabrina Bonde; Nicholas Zavazava
Journal:  Stem Cells       Date:  2006-06-22       Impact factor: 6.277

3.  Preimplantation-stage stem cells induce long-term allogeneic graft acceptance without supplementary host conditioning.

Authors:  Fred Fändrich; Xiongbin Lin; Gui X Chai; Maren Schulze; Detlev Ganten; Michael Bader; Julia Holle; Dong-Sheng Huang; Reza Parwaresch; Nicholaus Zavazava; Bert Binas
Journal:  Nat Med       Date:  2002-02       Impact factor: 53.440

4.  Peptide length variants p2Ca and QL9 present distinct conformations to L(d)-specific T cells.

Authors:  T M Hornell; S M Martin; N B Myers; J M Connolly
Journal:  J Immunol       Date:  2001-10-15       Impact factor: 5.422

5.  HoxB4 confers definitive lymphoid-myeloid engraftment potential on embryonic stem cell and yolk sac hematopoietic progenitors.

Authors:  Michael Kyba; Rita C R Perlingeiro; George Q Daley
Journal:  Cell       Date:  2002-04-05       Impact factor: 41.582

6.  Regulation of T cell receptor CD3zeta chain expression by L-arginine.

Authors:  Paulo C Rodriguez; Arnold H Zea; Kirk S Culotta; Jovanny Zabaleta; Juan B Ochoa; Augusto C Ochoa
Journal:  J Biol Chem       Date:  2002-04-11       Impact factor: 5.157

7.  Human embryonic stem cells and their differentiated derivatives are less susceptible to immune rejection than adult cells.

Authors:  Micha Drukker; Helena Katchman; Gil Katz; Smadar Even-Tov Friedman; Elias Shezen; Eran Hornstein; Ofer Mandelboim; Yair Reisner; Nissim Benvenisty
Journal:  Stem Cells       Date:  2005-08-18       Impact factor: 6.277

8.  Human embryonic stem cell-derived CD34+ cells: efficient production in the coculture with OP9 stromal cells and analysis of lymphohematopoietic potential.

Authors:  Maxim A Vodyanik; Jack A Bork; James A Thomson; Igor I Slukvin
Journal:  Blood       Date:  2004-09-16       Impact factor: 22.113

9.  De novo-developed T cells have compromised response to existing alloantigens: using Ld-specific transgenic 2C T cells as tracers in a mouse heart transplantation model.

Authors:  H Luo; H Chen; S Qi; D Loh; P Daloze; A Veillette; D Xu; J Wu
Journal:  J Immunol       Date:  1998-07-01       Impact factor: 5.422

10.  Characterization of the expression of MHC proteins in human embryonic stem cells.

Authors:  Micha Drukker; Gil Katz; Achia Urbach; Maya Schuldiner; Gal Markel; Joseph Itskovitz-Eldor; Benjamin Reubinoff; Ofer Mandelboim; Nissim Benvenisty
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-11       Impact factor: 11.205

View more
  2 in total

Review 1.  Progress toward establishing embryonic stem or induced pluripotent stem cell-based clinical translation.

Authors:  Nicholas Zavazava
Journal:  Curr Opin Organ Transplant       Date:  2014-12       Impact factor: 2.640

Review 2.  Skin deep: from dermal fibroblasts to pancreatic beta cells.

Authors:  Gohar S Manzar; Eun-Mi Kim; Pavana Rotti; Nicholas Zavazava
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.